Abstract：
UNASSIGNED: To identify and analyze the published in vitro benchtop experiments for the assessment of endovascular techniques used for the treatment of juxtarenal abdominal aortic aneurysms (jAAAs).
UNASSIGNED: Scopus, PubMed, and Web of Science.
UNASSIGNED: A systematic literature search was carried out throughout March 2021 following PRISMA guidelines. Two investigators independently performed title and abstract screening to reveal all benchtop testing evaluating the endovascular treatment of jAAA.
UNASSIGNED: A total of 19 studies were included, 8 evaluating fenestrated (FEVAR) and 11 parallel grafts (PGs). FEVAR studies used different custom testing apparatus (n=7) or 3D-printed models (n=1) to analyze dislodgement and migration resistance, misalignment consequences and causation, and bridging stents\' radial force, flareability, fatigue, and fracture resistance. All PG studies used silicone-based models to analyze optimal oversizing, sealing length, gutter behavior, and possible reduction. Test evaluation in FEVAR in vitro testing was based on pullout force analysis (N=5), photo evaluation (n=1), fluoroscopy (n=1), X-rays (n=4), CT analysis (n=3), macro- and microscopic evaluation (n=4), water permeability (n=1), and fatigue simulator testing (n=1), while it was based on CT analysis in all PG studies adding ECG-gate in one study. The most frequently tested devices were Zenit (Cook) (n=7), Endurant (Medtronic) (n=5), and Excluder (Gore) (n=5) as main grafts, and Advanta V12 (n=14) as the bridging device.
UNASSIGNED: This systematic review presents a broad analysis of the current in vitro methods evaluating the endovascular treatment of jAAA. Fundamental issues have been benchtop tested in both FEVAR and PGs. The analysis of the included studies allowed to recommend an optimal testing design. In vitro testing is a potential tool to further elucidate points of attention hard to investigate in vivo to finally enhance the endovascular treatment outcomes. Future in vitro studies are needed to evaluate the in vitro performance of all indistinctively used devices in the clinical practice.
UNASSIGNED: Scopus, PubMed, and Web of Science.
UNASSIGNED: A systematic literature search was carried out throughout March 2021 following PRISMA guidelines. Two investigators independently performed title and abstract screening to reveal all benchtop testing evaluating the endovascular treatment of jAAA.
UNASSIGNED: A total of 19 studies were included, 8 evaluating fenestrated (FEVAR) and 11 parallel grafts (PGs). FEVAR studies used different custom testing apparatus (n=7) or 3D-printed models (n=1) to analyze dislodgement and migration resistance, misalignment consequences and causation, and bridging stents\' radial force, flareability, fatigue, and fracture resistance. All PG studies used silicone-based models to analyze optimal oversizing, sealing length, gutter behavior, and possible reduction. Test evaluation in FEVAR in vitro testing was based on pullout force analysis (N=5), photo evaluation (n=1), fluoroscopy (n=1), X-rays (n=4), CT analysis (n=3), macro- and microscopic evaluation (n=4), water permeability (n=1), and fatigue simulator testing (n=1), while it was based on CT analysis in all PG studies adding ECG-gate in one study. The most frequently tested devices were Zenit (Cook) (n=7), Endurant (Medtronic) (n=5), and Excluder (Gore) (n=5) as main grafts, and Advanta V12 (n=14) as the bridging device.
UNASSIGNED: This systematic review presents a broad analysis of the current in vitro methods evaluating the endovascular treatment of jAAA. Fundamental issues have been benchtop tested in both FEVAR and PGs. The analysis of the included studies allowed to recommend an optimal testing design. In vitro testing is a potential tool to further elucidate points of attention hard to investigate in vivo to finally enhance the endovascular treatment outcomes. Future in vitro studies are needed to evaluate the in vitro performance of all indistinctively used devices in the clinical practice.
摘要：
UNASSIGNED：确定和分析已发表的体外基准实验，以评估用于治疗近肾腹主动脉瘤（jAAAs）的血管内技术。
未经批准：Scopus，PubMed,和WebofScience。
UNASSIGNED：按照PRISMA指南，在2021年3月进行了系统的文献检索。两名研究人员独立进行了标题和摘要筛选，以揭示评估jAAA血管内治疗的所有基准测试。
未经评估：共纳入19项研究，8评估开窗(FEVAR)和11个平行移植物(PG)。FEVAR研究使用不同的定制测试设备（n=7）或3D打印模型（n=1）来分析移位和迁移阻力，错位后果和因果关系，和桥接支架径向力，耀度，疲劳,和抗断裂性。所有PG研究都使用基于有机硅的模型来分析最佳尺寸过大，密封长度,排水沟行为，可能的减少。FEVAR体外测试中的测试评估基于拔出力分析(N=5)，照片评估(n=1)，透视（n=1），X射线（n=4），CT分析（n=3），宏观和微观评价(n=4)，透水性(n=1)，和疲劳模拟器测试(n=1)，而它是基于所有PG研究中的CT分析，在一项研究中添加了ECG门。最常测试的设备是Zenit(Cook)(n=7)，Endurant（美敦力公司）（n=5），和排除（戈尔）（n=5）作为主要移植物，和优点V12(n=14)作为桥接装置。
UNASSIGNED：本系统综述对评估jAAA血管内治疗的当前体外方法进行了广泛分析。基本问题已经在FEVAR和PG中进行了测试。对纳入研究的分析允许推荐最佳测试设计。体外测试是进一步阐明难以在体内研究的关注点以最终增强血管内治疗结果的潜在工具。需要未来的体外研究来评估临床实践中所有不明显使用的设备的体外性能。
未经批准：Scopus，PubMed,和WebofScience。
UNASSIGNED：按照PRISMA指南，在2021年3月进行了系统的文献检索。两名研究人员独立进行了标题和摘要筛选，以揭示评估jAAA血管内治疗的所有基准测试。
未经评估：共纳入19项研究，8评估开窗(FEVAR)和11个平行移植物(PG)。FEVAR研究使用不同的定制测试设备（n=7）或3D打印模型（n=1）来分析移位和迁移阻力，错位后果和因果关系，和桥接支架径向力，耀度，疲劳,和抗断裂性。所有PG研究都使用基于有机硅的模型来分析最佳尺寸过大，密封长度,排水沟行为，可能的减少。FEVAR体外测试中的测试评估基于拔出力分析(N=5)，照片评估(n=1)，透视（n=1），X射线（n=4），CT分析（n=3），宏观和微观评价(n=4)，透水性(n=1)，和疲劳模拟器测试(n=1)，而它是基于所有PG研究中的CT分析，在一项研究中添加了ECG门。最常测试的设备是Zenit(Cook)(n=7)，Endurant（美敦力公司）（n=5），和排除（戈尔）（n=5）作为主要移植物，和优点V12(n=14)作为桥接装置。
UNASSIGNED：本系统综述对评估jAAA血管内治疗的当前体外方法进行了广泛分析。基本问题已经在FEVAR和PG中进行了测试。对纳入研究的分析允许推荐最佳测试设计。体外测试是进一步阐明难以在体内研究的关注点以最终增强血管内治疗结果的潜在工具。需要未来的体外研究来评估临床实践中所有不明显使用的设备的体外性能。
